Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis
- PMID: 36479820
- DOI: 10.1111/bju.15944
Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis
Abstract
Objective: To assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified.
Methods: Multiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC.
Results: Overall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48-1.74) and PFS (pooled HR 1.44, 95% CI 1.18-1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69-2.30) and PFS (pooled HR 1.81, 95% CI 1.52-2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52-3.01) and PFS (pooled HR 2.17, 95% CI 1.42-3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25-2.72) and PFS (pooled HR 3.06, 95% CI 2.31-4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63-3.30).
Conclusions: Cystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.
Keywords: #BladderCancer; #blcsm; #uroonc; cystoscopy; gross appearance; multiplicity; non-muscle-invasive bladder cancer; progression; recurrence; size.
© 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Similar articles
-
A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.Eur Urol Oncol. 2024 Jun;7(3):438-446. doi: 10.1016/j.euo.2023.09.014. Epub 2023 Oct 11. Eur Urol Oncol. 2024. PMID: 37827948
-
Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.BJU Int. 2024 Oct;134(4):644-651. doi: 10.1111/bju.16371. Epub 2024 Apr 16. BJU Int. 2024. PMID: 38627025
-
Association Between Hypoglycemia Agents and Long-term Survival Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guérin Immunotherapy.Eur Urol Oncol. 2025 Feb;8(1):164-170. doi: 10.1016/j.euo.2024.12.002. Epub 2024 Dec 16. Eur Urol Oncol. 2025. PMID: 39689991
-
A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.Arch Ital Urol Androl. 2024 Feb 16;96(1):12154. doi: 10.4081/aiua.2024.12154. Arch Ital Urol Androl. 2024. PMID: 38363237
-
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10. Eur Urol. 2022. PMID: 34511303 Review.
Cited by
-
Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its nomogram.Front Oncol. 2025 Feb 3;15:1406585. doi: 10.3389/fonc.2025.1406585. eCollection 2025. Front Oncol. 2025. PMID: 39963109 Free PMC article.
-
Preoperative systemic inflammatory biomarkers can improve recurrence prediction of non-muscle invasive bladder cancer after endoscopic resection - a prospective observational study.Contemp Oncol (Pozn). 2025;29(2):188-194. doi: 10.5114/wo.2025.151064. Epub 2025 May 13. Contemp Oncol (Pozn). 2025. PMID: 40620890 Free PMC article.
References
-
- Babjuk M, Burger M, Capoun O et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022; 81: 75-94
-
- Cambier S, Sylvester RJ, Collette L et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin. Eur Urol 2016; 69: 60-9
-
- Fernandez-Gomez J, Madero R, Solsona E et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model. J Urol 2009; 182: 2195-203
-
- Sylvester RJ, Rodriguez O, Hernandez V et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 2021; 79: 480-8
-
- Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical